Company Profile
Graphite Bio Stock Price, News & Catalysts
- Ticker:
- GRPH
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for GRPH.
Company overview
Business overview
Graphite Bio was a gene-editing company focused on precision genome correction before its public-market wind-down. Its story was built around advanced editing science and rare-disease targets.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ before restructuring, Graphite sat in gene-editing biotechnology.
Business Model Characteristics
The business depended on clinical and translational validation, as well as the feasibility of its editing approach.
Position Within the Biotechnology Landscape
Graphite Bio is now best treated as a historical gene-editing case rather than a live catalyst name.
Future catalysts
- Graphite Bio is now mostly a legacy and closeout story, so the catalysts are any strategic or asset-disposition update rather than fresh pipeline news. The market no longer treats it like a live standalone development story.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Graphite Bio do?
Graphite Bio was a gene-editing company focused on precision genome correction before its public-market wind-down. Its story was built around advanced editing science and rare-disease targets.
On which exchange is GRPH stock listed?
Graphite Bio (GRPH) is associated with NASDAQ, United States, Biopharma.
What is Graphite?
Graphite Bio is now mostly a legacy and closeout story, so the catalysts are any strategic or asset-disposition update rather than fresh pipeline news.
Which conditions is Graphite Bio targeting with Graphite?
Graphite Bio is now mostly a legacy and closeout story, so the catalysts are any strategic or asset-disposition update rather than fresh pipeline news.
How does Graphite Bio describe recent progress with Graphite?
Graphite Bio is now mostly a legacy and closeout story, so the catalysts are any strategic or asset-disposition update rather than fresh pipeline news.
What future catalysts are investors watching for Graphite Bio?
Graphite Bio is now mostly a legacy and closeout story, so the catalysts are any strategic or asset-disposition update rather than fresh pipeline news. The market no longer treats it like a live standalone development story.